Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy with Vemurafenib in Metastatic Melanoma
NCT02354690Phase 2Completed
- Start
- Nov 2014
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in melanoma. Primary endpoint: Number of Reported Adverse Events. Started Nov 2014; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02354690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354690.